Medication info
Valsartan Tablet 160 mg (Valsartan)

Valsartan Tablet 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Oval-shaped film-coated tablet with an orange color and a grayish tint
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201702205 · Approved 2017.04.28 · Insurance code 649103440

Summary

Main use
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg per dose twice daily. Over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or greater. Do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is used to control blood pressure in patients with essential hypertension and effectively treats heart failure in patients who cannot use ACE inhibitors. It also helps reduce the risk of death in patients with decreased left ventricular function after myocardial infarction. It is used for improving conditions related to essential hypertension, heart failure, and post-myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg per dose twice daily. Over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or greater. Do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. It is advisable not to use this medication in patients with severely impaired liver function, liver cirrhosis, or cholestasis. Patients with hereditary angioedema or a history of angioedema while taking ACE inhibitors or angiotensin II receptor antagonists may be at risk if taking this medication. It is safer not to combine this medication with patients who have severe renal impairment, primary hyperaldosteronism, or moderate to severe renal impairment among diabetes patients. Elderly patients, those with hyperkalemia, or patients with mild liver dysfunction should take special care, particularly to avoid dropping blood pressure too low and adjust the dosage slowly. Patients with heart failure or post-myocardial infarction may experience worsening kidney function, so regular kidney function tests should be performed, and careful monitoring is necessary when combined with other antihypertensives. Taking this medication may cause side effects such as headache, dizziness, fatigue, cough, and diarrhea, so if any unusual symptoms occur, it is necessary to consult a doctor. Blood pressure may drop suddenly, leading to dizziness or fainting, so it is recommended to start with a low dose and monitor the condition closely. This medication can increase potassium levels, so when used in conjunction with potassium-sparing diuretics or potassium supplements, blood potassium levels should be monitored carefully. Caution is required when taken with nonsteroidal anti-inflammatory drugs (NSAIDs) as it can reduce the antihypertensive effect or worsen kidney function. When taken in conjunction with lithium preparations, there may be an increase in blood lithium levels resulting in toxicity, thus regular monitoring of blood levels is necessary. While taking this medication, care should be taken when driving or operating machinery as dizziness or drowsiness may occur. In case of overdose, contact a medical institution immediately for appropriate treatment, and if symptoms of low blood pressure occur, lying down and intravenous fluid treatment may be necessary. This medication should be kept out of reach of children, and it is not advisable to transfer it to another container as it may negatively affect quality.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 52 more
  • pain in the abdomen
  • nausea
  • pharyngitis
  • joint pain
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal impairment
  • hyperkalemia
  • angioedema
  • heart failure
  • vascular edema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • syncope
  • epistaxis
  • hepatitis
  • arrhythmia
  • intestinal vascular edema
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatitis
  • reduced red blood cell volume
  • decreased hemoglobin
  • neutropenia
  • increased serum creatinine
  • increased total bilirubin
  • increased BUN
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • loss of appetite
  • malaise
  • dyspepsia
  • anemia
  • tinnitus
  • hypertonia
  • decreased motor function
  • confusion
  • chest pain
  • rash
  • myalgia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air and moisture, and should be kept in a cool place below 30 degrees Celsius. Storing it this way helps maintain its effectiveness for a longer period.

Appearance and packaging

Appearance

Oval-shaped film-coated tablet with an orange color and a grayish tint

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.